Shilpa Medicare Ltd
NSE: SHILPAMED BSE: 530549
₹336
(-0.78%)
Thu, 12 Mar 2026, 11:54 pm
Market Cap66.29B
PE Ratio43.81
Dividend0.15
Health Technology
Pharmaceuticals: Major
24.5KShilpa Medicare Analysis
dividend
- Shilpa Medicare is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
- No need to calculate the sustainability of Shilpa Medicare's dividends as it is not paying a notable one for India.
- No need to calculate the sustainability of Shilpa Medicare's dividends in 3 years as they are not expected to pay a notable one for India.
- Shilpa Medicare is not paying a notable dividend for India, therefore no need to check if the payments are stable.
- Shilpa Medicare's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Shilpa Medicare's dividend is below the markets top 25% of dividend payers in India (3.08%).
future
- Cash flow for Shilpa Medicare is expected to increase by more than 50% in 2 years time.
- Shilpa Medicare's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- Shilpa Medicare's earnings are expected to exceed the low risk growth rate next year.
- Shilpa Medicare's earnings are expected to grow by 8.3% yearly, however this is not considered high growth (20% yearly).
- Shilpa Medicare's earnings growth is positive but not above the India market average.
- Shilpa Medicare is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
- Performance (ROE) is not expected to exceed the current IN Pharmaceuticals industry average.
- A decline in Shilpa Medicare's performance (ROE) is expected over the next 3 years.
health
- Shilpa Medicare is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Shilpa Medicare is profitable, therefore cash runway is not a concern.
- Shilpa Medicare is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (36.2%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 2.6x debt.
- Shilpa Medicare's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (32.8% vs 18.2% today).
- Shilpa Medicare earns more interest than it pays, coverage of interest payments is not a concern.
- Shilpa Medicare's level of debt (18.2%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- Vishnukanth's compensation has been consistent with company performance over the past year, both up more than 20%.
- The average tenure for the Shilpa Medicare board of directors is less than 3 years, this suggests a new board.
- Vishnukanth's remuneration is higher than average for companies of similar size in India.
misc
- Shilpa Medicare is covered by less than 3 analysts.
- Shilpa Medicare has significant price volatility in the past 3 months.
past
- Shilpa Medicare's 1-year earnings growth exceeds its 5-year average (21.9% vs 8.6%)
- Shilpa Medicare's year on year earnings growth rate has been positive over the past 5 years.
- Shilpa Medicare used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Shilpa Medicare's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Shilpa Medicare has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Shilpa Medicare's earnings growth has not exceeded the IN Pharmaceuticals industry average in the past year (21.9% vs 22.7%).
value
- 530549 outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 530549 outperformed the Market in India which returned -14.5% over the past year.
- BSE:530549 is up 46.7% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:530549 is up 46.7% outperforming the market in India which returned 8% over the past month.
- Shilpa Medicare's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Shilpa Medicare's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Shilpa Medicare is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Shilpa Medicare is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Shilpa Medicare is overvalued based on earnings compared to the India market.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800